Skip to content
Screener

4D Molecular Therapeutics FDMT Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue$3.8MBeat by $161.0K
EPS-$1.04Miss by $0.02
Revenue estimate$3.6M
EPS estimate-$1.02
“With topline data from both 4FRONT-1 and 4FRONT-2 in wet AMD expected in 2027, our DME Phase 3 expected to initiate in the third quarter and our Investor Day planned in October, we are well positioned to advance 4D-150 as a potential paradigm-changing backbone therapy for patients with wet AMD and DME.”
David Kirn

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$3.5M
EPS estimate-$1.04

Financials

Q2 2026

Income statement

See full
Revenue$3.8M+25,107%
Operating income-$77.0M-29.5%
Net income-$72.9M-33.4%
EPS (diluted)-$1.04-6.1%

Balance sheet

See full
Cash & equivalents$70.4M-8.8%
Total debt$39.2M+69.9%
Total equity$407.7M-3.1%
Total assets$492.6M+4.0%

Cash flow

See full
Operating cash flow-$70.0M-61.4%
CapEx$55.0K-90.1%
Free cash flow-$70.1M-59.5%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$760.16M+144%
Enterprise value$729.01M+184%
P/S8.3×-9,415×

Profitability

See full
Operating margin-230.2%-115pp

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio8×-0.7×

Segments

By geography

See full
JP$3.7M—
US$90.0K+500%

By product

See full
Collaboration And License Revenue$3.8M+25,107%

FAQ

When did 4D Molecular Therapeutics report Q2 2026 earnings?
4D Molecular Therapeutics (FDMT) reported Q2 2026 earnings on August 13, 2026 after market close.
What were 4D Molecular Therapeutics's Q2 2026 revenue and EPS?
4D Molecular Therapeutics reported revenue of $3.8M and eps of $-1.04 for Q2 2026.
Did 4D Molecular Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $3.6M by $161.0K. EPS missed the consensus estimate of $-1.02 by $0.02.
How did 4D Molecular Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 25106.7% from $15.0K a year earlier and eps declined 6.1% from $-0.98.
Where can I find 4D Molecular Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-349160) and the 10-Q periodic report (0001193125-26-349173) directly on SEC EDGAR. The filing index links above go to sec.gov.